Rice Hall James & Associates’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $56.6M | Buy |
283,567
+3,940
| +1% | +$780K | 3.15% | 1 |
|
|
2025
Q4 | $52.9M | Sell |
279,627
-14,863
| -5% | -$2.86M | 2.91% | 1 |
|
|
2025
Q3 | $52.2M | Sell |
294,490
-42,858
| -13% | -$6.37M | 2.84% | 3 |
|
|
2025
Q2 | $38.3M | Buy |
337,348
+40,127
| +14% | +$4.29M | 2.07% | 9 |
|
|
2025
Q1 | $31.2M | Sell |
297,221
-7,704
| -3% | -$871K | 1.84% | 12 |
|
|
2024
Q4 | $32.7M | Sell |
304,925
-7,954
| -3% | -$899K | 1.79% | 13 |
|
|
2024
Q3 | $31.3M | Buy |
312,879
+20,404
| +7% | +$2.05M | 1.69% | 14 |
|
|
2024
Q2 | $24.6M | Buy |
292,475
+12,691
| +5% | +$1.01M | 1.48% | 16 |
|
|
2024
Q1 | $20.5M | Buy |
279,784
+3,776
| +1% | +$278K | 1.17% | 21 |
|
|
2023
Q4 | $19.7M | Sell |
276,008
-6,953
| -2% | -$410K | 1.14% | 22 |
|
|
2023
Q3 | $17M | Sell |
282,961
-5,198
| -2% | -$342K | 1.08% | 22 |
|
|
2023
Q2 | $20.8M | Sell |
288,159
-186
| -0.1% | -$14K | 1.18% | 21 |
|
|
2023
Q1 | $21.2M | Buy |
288,345
+2,711
| +0.9% | +$193K | 1.2% | 22 |
|
|
2022
Q4 | $19.1M | Sell |
285,634
-189,941
| -40% | -$12.3M | 1.09% | 22 |
|
|
2022
Q3 | $25.5M | Sell |
475,575
-60,856
| -11% | -$3.58M | 1.48% | 13 |
|
|
2022
Q2 | $29.9M | Sell |
536,431
-16,554
| -3% | -$939K | 1.44% | 15 |
|
|
2022
Q1 | $38.8M | Sell |
552,985
-4,376
| -0.8% | -$317K | 1.55% | 16 |
|
|
2021
Q4 | $53.7M | Sell |
557,361
-41,712
| -7% | -$3.85M | 1.91% | 11 |
|
|
2021
Q3 | $52.1M | Sell |
599,073
-8,025
| -1% | -$621K | 1.92% | 8 |
|
|
2021
Q2 | $49.7M | Sell |
607,098
-82,282
| -12% | -$6.84M | 1.77% | 11 |
|
|
2021
Q1 | $65.6M | Sell |
689,380
-118,787
| -15% | -$11.2M | 2.14% | 7 |
|
|
2020
Q4 | $50.1M | Buy |
808,167
+188,598
| +30% | +$10.8M | 1.76% | 15 |
|
|
2020
Q3 | $36.8M | Buy |
619,569
+87,790
| +17% | +$5.99M | 1.48% | 16 |
|
|
2020
Q2 | $37.1M | Sell |
531,779
-10,638
| -2% | -$674K | 1.59% | 15 |
|
|
2020
Q1 | $24.6M | Buy |
542,417
+57,505
| +12% | +$3.26M | 1.38% | 18 |
|
|
2019
Q4 | $31.5M | Sell |
484,912
-21,242
| -4% | -$1.42M | 1.07% | 26 |
|
|
2019
Q3 | $31.4M | Sell |
506,154
-10,405
| -2% | -$653K | 1.12% | 25 |
|
|
2019
Q2 | $36.8M | Sell |
516,559
-31,893
| -6% | -$2.35M | 1.22% | 17 |
|
|
2019
Q1 | $43M | Buy |
548,452
+107,760
| +24% | +$8.16M | 1.38% | 14 |
|
|
2018
Q4 | $37.3M | Buy |
440,692
+133,988
| +44% | +$14.3M | 1.36% | 15 |
|
|
2018
Q3 | $52.5M | Sell |
306,704
-121,169
| -28% | -$18.3M | 1.88% | 7 |
|
|
2018
Q2 | $55.3M | Sell |
427,873
-60,548
| -12% | -$6.76M | 2.01% | 5 |
|
|
2018
Q1 | $50.3M | Sell |
488,421
-3,472
| -0.7% | -$343K | 1.96% | 5 |
|
|
2017
Q4 | $42M | Buy |
491,893
+62,267
| +14% | +$5.4M | 1.65% | 10 |
|
|
2017
Q3 | $36.5M | Sell |
429,626
-18,223
| -4% | -$1.44M | 1.61% | 6 |
|
|
2017
Q2 | $33.9M | Buy |
447,849
+95,990
| +27% | +$6.71M | 1.48% | 7 |
|
|
2017
Q1 | $23.2M | Buy |
351,859
+14,307
| +4% | +$941K | 1.13% | 11 |
|
|
2016
Q4 | $21.4M | Buy |
337,552
+2,751
| +0.8% | +$174K | 1.08% | 22 |
|
|
2016
Q3 | $21.3M | Buy |
334,801
+36,917
| +12% | +$2.71M | 1.11% | 15 |
|
|
2016
Q2 | $22.2M | Buy |
297,884
+2,337
| +0.8% | +$173K | 1.28% | 10 |
|
|
2016
Q1 | $19.7M | Buy |
295,547
+6,347
| +2% | +$386K | 1.14% | 22 |
|
|
2015
Q4 | $19.6M | Buy |
289,200
+123,309
| +74% | +$7.61M | 1.12% | 21 |
|
|
2015
Q3 | $8.86M | Buy |
165,891
+13,662
| +9% | +$829K | 0.57% | 59 |
|
|
2015
Q2 | $9.58M | Sell |
152,229
-15,113
| -9% | -$825K | 0.55% | 62 |
|
|
2015
Q1 | $8.05M | Buy |
+167,342
| New | +$6.41M | 0.47% | 71 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Rice Hall James & Associates's LGND Position: Q1 2026 in Review
Rice Hall James & Associates increased its Ligand Pharmaceuticals (LGND) stake by 1.4% in Q1 2026, buying an estimated $780K and bringing the position to 283,567 shares worth $56.6M. The position accounts for 3.15% of the portfolio, ranked #1.
Rice Hall James & Associates first reported a position in LGND in Q1 2015 and has held it in 45 quarters since. The position peaked at $65.6M in Q1 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Rice Hall James & Associates held 283,567 shares of Ligand Pharmaceuticals worth $56.6M as of Q1 2026.
- Rice Hall James & Associates bought 3,940 Ligand Pharmaceuticals shares in Q1 2026, an estimated $780K.
- Ligand Pharmaceuticals made up 3.15% of Rice Hall James & Associates's portfolio in Q1 2026, its #1 holding.
- Rice Hall James & Associates first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- Rice Hall James & Associates's Ligand Pharmaceuticals position peaked at $65.6M in Q1 2021.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.